在美国的试验中,HOPE心脏系统改善了移植机会,91.4%的人一年存活. HOPE heart system improves transplant access with 91.4% one-year survival in U.S. trial.

在一场医学会议上,XVIVO Perfusion 公司展示了其 HOPE 心脏保护系统的新数据. XVIVO Perfusion presented new data on its HOPE heart preservation system at a medical conference. 美国的 The U.S. 接受扩展标准捐赠心脏的患者,平均保存时间为291分钟. PRESERVE trial showed 91.4% one-year survival for patients receiving extended criteria donor hearts, with an average preservation time of 291 minutes. 这项研究涉及141名成年人,达到主要安全性和有效性的终点,支持该设备改善移植的潜力. The study, involving 141 adults, met primary safety and efficacy endpoints, supporting the device's potential to improve access to transplants.